Literature DB >> 19269261

Erythromycin improves gastric emptying half-time in adult cystic fibrosis patients with gastroparesis.

Adriano R Tonelli1, Walter E Drane, Dennis P Collins, Wanda Nichols, Veena B Antony, Eric L Olson.   

Abstract

BACKGROUND: Gastrointestinal manifestations are frequently encountered in cystic fibrosis patients. Gastroparesis evidenced by a variety of diagnostic methods has been described in patients with cystic fibrosis, predominantly in children and in individuals with advanced lung disease. The presence of gastroparesis in adult patients with different degrees of lung involvement and its response to the acute and chronic administration of macrolides have not been reported.
METHODS: Using the University of Florida Cystic Fibrosis database we identified symptomatic patients who had gastroparesis confirmed by a prolonged half-time during gastric emptying scintigraphy.
RESULTS: Of 86 cystic fibrosis patients, periodically followed in our institution, we found five who had classical symptoms and prolonged gastric emptying half-time. Age 25.2+/-8 years, 80% females, BMI 22+/-9 kg/m(2), HbA1c 5.8+/-0.6 g/dl, FEV1 53.2+/-15% of predicted. Gastric emptying half-time was 191.4+/-91.4 min (range 100-300 min) and decreased to 12.2+/-6 min (range 5-20 min) after IV administration of erythromycin (p=0.043). Patients were followed up for 3+/-2.1 years. All patients but one, who was taking opiods, had good clinical response to PO macrolides.
CONCLUSIONS: Gastroparesis occurs in patients with cystic fibrosis, even in patients with relatively preserved lung function and in those without cystic-fibrosis related diabetes. Macrolides may be an effective therapy in cystic fibrosis patients with gastroparesis when administered acutely or chronically.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19269261     DOI: 10.1016/j.jcf.2009.02.001

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  5 in total

Review 1.  Luminal Gastrointestinal Manifestations of Cystic Fibrosis.

Authors:  Samuel J Burton; Christine Hachem; James M Abraham
Journal:  Curr Gastroenterol Rep       Date:  2021-03-23

Review 2.  Pathophysiology of cystic fibrosis and drugs used in associated digestive tract diseases.

Authors:  Adriana Haack; Giselle Gonçalves Aragão; Maria Rita Carvalho Garbi Novaes
Journal:  World J Gastroenterol       Date:  2013-12-14       Impact factor: 5.742

Review 3.  Understanding Cystic Fibrosis Comorbidities and Their Impact on Nutritional Management.

Authors:  Dhiren Patel; Albert Shan; Stacy Mathews; Meghana Sathe
Journal:  Nutrients       Date:  2022-02-28       Impact factor: 5.717

Review 4.  CFTR Modulators: Does One Dose Fit All?

Authors:  Renske van der Meer; Erik B Wilms; Harry G M Heijerman
Journal:  J Pers Med       Date:  2021-05-24

Review 5.  Is Gastroparesis Found More Frequently in Patients with Cystic Fibrosis? A Systematic Review.

Authors:  Juan E Corral; Corey W Dye; Maria R Mascarenhas; Jamie S Barkin; Matthias Salathe; Baharak Moshiree
Journal:  Scientifica (Cairo)       Date:  2016-05-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.